Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1995 1
1996 4
1997 1
1999 2
2000 2
2001 1
2002 1
2003 4
2004 5
2005 1
2006 5
2007 3
2008 5
2009 4
2010 4
2011 6
2012 8
2013 6
2014 8
2015 8
2016 9
2017 3
2018 11
2019 10
2020 5
2021 7
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

115 results
Results by year
Filters applied: . Clear all
Page 1
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, Matlung HL, Fauster A, Gomez-Eerland R, Bakker NAM, van der Schot S, Marijt KA, Verdoes M, Haanen JBAG, van den Berg JH, Neefjes J, van den Berg TK, Brummelkamp TR, Leusen JHW, Scheeren FA, Schumacher TN. Logtenberg MEW, et al. Among authors: leusen jhw. Nat Med. 2019 Apr;25(4):612-619. doi: 10.1038/s41591-019-0356-z. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833751 Free PMC article.
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.
Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK. Matlung HL, et al. Among authors: leusen jhw. Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082. Cell Rep. 2018. PMID: 29949776 Free article.
IgA as therapeutic antibody.
Leusen JH. Leusen JH. Mol Immunol. 2015 Nov;68(1):35-9. doi: 10.1016/j.molimm.2015.09.005. Mol Immunol. 2015. PMID: 26597204 Review.
Identification of a tumor-specific allo-HLA-restricted γδTCR.
Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, Schiffler M, Aarts-Riemens T, Kramer L, Straetemans T, Heijhuurs S, Leusen JHW, San José E, Fuchs K, Griffioen M, Falkenburg JH, Bongiovanni L, de Bruin A, Vargas-Diaz D, Altelaar M, Heck AJR, Shultz LD, Ishikawa F, Nishimura MI, Sebestyén Z, Kuball J. Kierkels GJJ, et al. Among authors: leusen jhw. Blood Adv. 2019 Oct 8;3(19):2870-2882. doi: 10.1182/bloodadvances.2019032409. Blood Adv. 2019. PMID: 31585951 Free PMC article.
CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
Valerius T, Rösner T, Leusen JHW. Valerius T, et al. Among authors: leusen jhw. N Engl J Med. 2019 Jan 31;380(5):496-7. doi: 10.1056/NEJMc1816156. N Engl J Med. 2019. PMID: 30702240 No abstract available.
ARGX-117, a therapeutic complement inhibiting antibody targeting C2.
Van de Walle I, Silence K, Budding K, Van de Ven L, Dijkxhoorn K, de Zeeuw E, Yildiz C, Gabriels S, Percier JM, Wildemann J, Meeldijk J, Simons PJ, Boon L, Cox L, Holgate R, Urbanus R, Otten HG, Leusen JHW, Blanchetot C, de Haard H, Hack CE, Boross P. Van de Walle I, et al. Among authors: leusen jhw. J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7. doi: 10.1016/j.jaci.2020.08.028. Epub 2020 Sep 11. J Allergy Clin Immunol. 2021. PMID: 32926878 Free PMC article.
115 results